Table 1

Clinicopathological data

All (n=481)%
Age (year, range)6965–91
Year at diagnosis
 1979–2000132.7
 2000–2009245.0
 2010–201919941.4
 2000–202224550.9
Education (year)
 ≤6459.4
 7–913327.7
 10–1216233.7
 ≥1314129.3
 CCI (median, range)20–11
Stage
 Early36976.7
 Metastatic11223.3
Molecular subtype
 HR+/HER2−33068.6
 HER2+9519.8
 HR−/HER2−438.9
 Unknown132.7
Surgery
 Yes43891.1
 No438.9
Chemotherapy
 Yes27256.5
 No/unknown20943.5
Radiotherapy
 Yes14530.1
 No/unknown33669.9
Endocrine therapy
 Yes31465.3
 No/unknown16734.7
 Step of treatment*369
 Pre-chemotherapy8623.3
 During chemotherapy4010.8
 Post-chemotherapy/during endocrine therapy24365.9
Median time from enrolment to active treatment (month, range)†44(1–336)

  • *This point applies to early stage patients (n=369).

  • †This point applies to early stage patients after chemotherapy or during endocrine therapy (n=243).

  • CCI, Charlson Comorbidity Index; HER2, human epidermal growth factor receptor 2; HR, hormone receptor.